Alpine Immune Sciences, Inc. Alternatives & Competitors

12 companies similar to Alpine Immune Sciences, Inc. — Leading the Next Evolution of Immunotherapies

Jnana Therapeutics

92 Series C $207.00M

Boston, United States

Biotechnology Health Care +1

Compare

Eikon Therapeutics

Eikon is a late-stage clinical biopharmaceutical company dedicated to inventing and develo...

429 Series D $1.12B

Millbrae, United States

Biotechnology Health Care +1

Compare

Biond Biologics Ltd

Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics f...

43 Series C $32.00M

Israel

Biotechnology Health Care +1

DBV Technologies

On a mission to advance epicutaneous immunotherapy using our innovative technology platfor...

187 Post-IPO Equity $239.80M

Chatillon, France

Biopharma Biotechnology +1

Compare

Track all Alpine Immune Sciences, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

AnaptysBio

Transforming patient health by delivering innovative immunology therapeutics.

144 IPO $185.90M

San Diego, United States

Biotechnology Health Care +1

SFA Therapeutics

A New Paradigm in Drug Development

9 Convertible Note $8.73M

Jenkintown, United States

Biotechnology Health Care +1

Allakos Inc

Antibody-based therapeutics to treat various allergies and diseases

24 Acquired $388.00M

Redwood City, United Stat...

Biopharma Biotechnology +2

Georgiamune Inc.

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...

30 Series A $75.00M

Gaithersburg, United Stat...

Biotechnology Health Care +1

Promedior

Pioneering advanced therapies to heal fibrotic and inflammatory diseases at their source,...

Venture round $63.00M

Biopharma Biotechnology +2

Enlivex Therapeutics (Nasdaq: ENLV)

Immune rebalancing

41 Post-IPO Equity

Israel

Biotechnology Health Care +1

Santa Ana Bio, Inc.

Precision medicines for serious immune mediated diseases.

34 Series B $176.02M

Alameda, United States

Biotechnology Health Care +1

Tridek-One

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...

12 Venture round $19.00M

Paris, France

Biotechnology Health Care +1

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is a leading player in the biotechnology and health care industries. Founded in 2015, the company has now become a part of Vertex Pharmaceuticals, a global biotechnology company with a focus on transformative medicines for individuals with serious diseases.

Business keywords

Clinical-stage Biopharmaceutical, Immunotherapy, Autoimmune Diseases, Inflammatory Diseases, Protein-based Therapies, Immune Synapse Targeting, Drug Development, Patented Scientific Platform, ALPN-303, Povetacicept, BAFF Antagonist, APRIL Antagonist, ALPN-101, Acazicolcept, ICOS Antagonist

Frequently Asked Questions

Companies similar to Alpine Immune Sciences, Inc. include Jnana Therapeutics, Eikon Therapeutics, Biond Biologics Ltd, DBV Technologies, AnaptysBio. They work in Biotechnology and Health Care and share Alpine Immune Sciences, Inc.'s focus on immunotherapy, autoimmune diseases and inflammatory diseases.

Bounce Watch lists 12 companies that share Alpine Immune Sciences, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Alpine Immune Sciences, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Alpine Immune Sciences, Inc. Profile Jnana Therapeutics Alternatives Eikon Therapeutics Alternatives Biond Biologics Ltd Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Alpine Immune Sciences, Inc. on 11 Sep 2024. The 12 companies listed here were last checked between 12 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.